https://www.frontiersin.org/articles/10.3389/fcell.2022.951764/full
Liu C, Xiao K and Xie L (2022),
Advances in mesenchymalstromal cell therapy for acute lung injury/acute respiratory distress syndrome.
Front. Cell Dev. Biol. 10:951764. doi: 10.3389/fcell.2022.951764
Acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) develops rapidly and has high mortality. ALI/ARDS is mainly manifested as acute or progressive hypoxic respiratory failure. At present, there is no effective clinical intervention for the treatment of ALI/ARDS. Mesenchymal stromal cells (MSCs) show promise for ALI/ARDS treatment due to their biological characteristics, easy cultivation, low immunogenicity, and abundant sources. The therapeutic mechanisms of MSCs in diseases are related to their homing capability, multidirectional differentiation, anti-inflammatory effect, paracrine signaling, macrophage polarization, the polarization of the MSCs themselves, and MSCs-derived exosomes. In this review, we discuss the pathogenesis of ALI/ARDS along with the biological characteristics and mechanisms of MSCs in the treatment of ALI/ARDS.
Cell Therapy News/Articles, page-14094
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.07 |
Change
0.040(3.88%) |
Mkt cap ! $1.221B | |||
| Open | High | Low | Value | Volume |
| $1.05 | $1.09 | $1.03 | $4.794M | 4.490M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 40 | 99002 | $1.07 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.07 | 11538 | 20 |
View Market Depth
| Last trade - 14.52pm 02/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |